Manuel Hidalgo, MD, PhD


Manuel Hidalgo received his MD degree from the University of Navarra, Pamplona, Spain in 1992 and his PhD degree from the Universiad Autonoma de Madrid, Spain in 1997. Dr.Hidalgo trained in Medical Oncology at the University Hospital '12 de Octubre' in Madrid, obtaining his Medical Oncology degree in 1996. He trained in drug development at the Institute for Drug Development of the University of Texas Health Science Center in San Antonio, USA. After a brief period as an Assistant Professor at the University of Texas Health Science Center, Dr. Hidalgo joined the Johns Hopkins University Kimmel Cancer Center in 2001 where he stayed, as co-director of the drug development program, and GI Programme until 2009. In 2003, Dr. Hidalgo and other colleagues founded the Pancreatic Cancer Research Team (PCRT), a cooperative clinical trials group that focuses on novel Therapeutics for patients with pancreatic cancer. Dr. Hidalgo joined the CNIO in 2009 to lead a Unit in Clinical Research in GI Cancer. Dr. Hidalgo has participated in the clinical development of more than 20 new agents including recently approved drugs such as erlotinib and temsirolimus. He has published more than 160 papers in peer review journals and his work has been funded uninterruptedly by the NCI, AACR, and ASCO and other funding agencies. His most recent efforts focus in novel therapeutic for pancreatic cancer.